OmniAb (OmniAb) Cash-to-Debt : 3.40 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is OmniAb Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. OmniAb's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.40.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, OmniAb could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for OmniAb's Cash-to-Debt or its related term are showing as below:

OABI' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.4 Med: 3.41 Max: 3.42
Current: 3.4

During the past 5 years, OmniAb's highest Cash to Debt Ratio was 3.42. The lowest was 3.40. And the median was 3.41.

OABI's Cash-to-Debt is ranked worse than
60.09% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs OABI: 3.40

OmniAb Cash-to-Debt Historical Data

The historical data trend for OmniAb's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

OmniAb Cash-to-Debt Chart

OmniAb Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

N/A

3.42

3.40

OmniAb Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial								3.42	4.39	3.89	3.69	3.40

Competitive Comparison of OmniAb's Cash-to-Debt

For the Biotechnology subindustry, OmniAb's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OmniAb's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where OmniAb's Cash-to-Debt falls into.

OmniAb Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

OmniAb's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	86.983	/	(3.486	+	22.075)
	=	3.40

OmniAb's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	86.983	/	(3.486	+	22.075)
	=	3.40

OmniAb (NAS:OABI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

OmniAb Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of OmniAb's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

OmniAb (OmniAb) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608

Website

https://www.omniab.com

OmniAb Inc offers therapeutic antibody discovery technologies. Its focus is to enable the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully-human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Executives

Matthew W Foehr	director, officer: President & CEO	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Steven Love	director	C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran	director	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean	director, 10 percent owner	65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler	director, 10 percent owner	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Kurt A Gustafson	officer: EVP, Finance and CFO	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Sarah Boyce	director	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010